Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Lansoprazole

A proton pump inhibitor that reduces acid production in the stomach: developed in Japan, patented in 1984 and on the market since the early 1990s, it is used for reflux, ulcers and Helicobacter pylori eradication. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?In 2015 a team at the Swiss Federal Institute of Technology in Lausanne found that, once converted inside cells into lansoprazole sulfide, it attacks the tuberculosis bacterium, including resistant strains.

LansoprazoleGo to the active ingredient →
LansoprazoleActive ingredientLansoprazoleCat. No. P-L015-001CAS 103577-45-3

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.